Glooko Receives FDA Clearance for EndoTool IV Cloud
Glooko, Inc. has announced that it received FDA 510(k) clearance for EndoTool IV Cloud, the first cloud-based, patient-specific insulin dosing platform approved by the FDA. This platform aims to enhance glycemic safety and diabetes management for clinicians.
PALO ALTO, Calif.–(BUSINESS WIRE)–Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for EndoTool IV Cloud, the first FDA-cleared, cloud-based patient-specific insulin dosing platform. EndoTool IV Cloud is the cloud-based version of EndoTool IV, Glooko’s clinical decision supp